Relmada Therapeutics (RLMD) Prepaid Assets (2012 - 2026)
Relmada Therapeutics (RLMD) reported Prepaid Assets of $1.4 million for Q1 2026, up 918.56% year-over-year from $135500.0 in Q1 2025, and up 41.16% quarter-over-quarter from $977721.0 in Q4 2025.
Relmada Therapeutics (RLMD) Prepaid Assets (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 14 years of Prepaid Assets data on file, last reported at $1.4 million in Q1 2026.
- Prepaid Assets for Q1 2026 came in at $1.4 million, up 918.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (up 918.56% YoY), and the FY2025 annual result was $977721.0, up 10.29% from the prior year.
- Prepaid Assets advanced to $1.4 million in Q1 2026 per RLMD's latest filing, from $977721.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $5.1 million in Q1 2022 and troughed at $125000.0 in Q4 2023.
- A 5-year average of $1.9 million and a median of $977721.0 in 2025 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets surged 2851.03% in 2022, then plunged 96.9% in 2023.
- A 5-year view of Prepaid Assets shows it stood at $4.0 million in 2022, then sank by 96.9% to $125000.0 in 2023, then jumped by 609.17% to $886461.0 in 2024, then gained by 10.29% to $977721.0 in 2025, then jumped by 41.16% to $1.4 million in 2026.
- Business Quant data shows RLMD's Prepaid Assets at $1.4 million in Q1 2026, $977721.0 in Q4 2025, and $967745.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 977,721.00 |
| Sep 30, 2025 | 967,745.00 |
| Jun 30, 2025 | 307,100.00 |
| Mar 31, 2025 | 135,500.00 |
| Dec 31, 2024 | 886,461.00 |
| Sep 30, 2024 | 611,200.00 |
| Jun 30, 2024 | 537,522.00 |
| Mar 31, 2024 | 752,334.00 |
| Dec 31, 2023 | 125,000.00 |
| Sep 30, 2023 | 2.83 Mn |
| Jun 30, 2023 | 3.47 Mn |
| Mar 31, 2023 | 3.09 Mn |
| Dec 31, 2022 | 4.04 Mn |
| Sep 30, 2022 | 2.95 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Mar 31, 2022 | 5.06 Mn |
| Dec 31, 2021 | 228,400.00 |
| Sep 30, 2021 | 2.72 Mn |
| Jun 30, 2021 | 1.55 Mn |